The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia
This podcast reports on a phase I/II trial investigating novel anti-CD22, moxetumomab pasudotox, in the treatment of patients with refractory hairy cell leukemia, which demonstrated responses in the majority of patients at all dose levels.